Floatz logo

2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID

Primary Biliary Cholangitis

Intercept PharmaceuticalsSmall moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Primary Biliary Cholangitis cohort.

Asset / SponsorPhaseRating
URSODEOXYCHOLIC ACID
Xijing Hospital of Digestive Diseases
Phase 4A
Fenofibrate
Xijing Hospital of Digestive Diseases
Phase 3BB
Saroglitazar
Zydus Therapeutics Inc.
Phase 3BB
Mbx-8025
Gilead Sciences
Phase 3BB
Obeticholic Acid
Intercept Pharmaceuticals
Phase 3BB

View all 50 →

Same molecule, other indications

2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID is also rated in:

HypercholesterolemiaDormant
BB
Indicative ·
68 / 100
View asset →
acute coronary syndromeDormant
BB
Indicative ·
65 / 100
View asset →
Non Optimal Response to UDCADormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →